Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance the lead program CYT-X300 to the ...

The MTHFD enzyme family is central to one-carbon metabolism, with MTHFD2 showing cancer-selective overexpression linked to poor prognosis. Emerging data also identify MTHFD1 as a therapeutic ...

South Korea’s Ministry of Food and Drug Safety (MFDS) approved Curocell Inc.’s Rimqarto (anbalcabtagene-autoleucel; anbal-cel ...

For the first time in 13 years, the U.S. Trade Representative (USTR) singled out one of the U.S. trading partners as the worst of the worst when it named Vietnam as a Priority Foreign Country (PFC) in ...

As Celcuity Inc. awaits a U.S. FDA approval decision for gedatolisib in HER-positive, HER2-negative, PIK3CA wild-type advanced breast cancer, the company already is setting its sights on a ...

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Ascendant Health Sciences, Cue, Esperion, Eton, J&J, Noxopharm.

Entering what Mirum Pharmaceuticals Inc. CEO Chris Peetz called “a new phase of growth and value creation,” the company plans to submit an NDA to the U.S. FDA in the second half of this year, based on ...

Beijing Danatlas Pharmaceutical Technology Co. Ltd. has patented new crystalline salt forms of poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.

BLR Bio LLC has presented new data highlighting the potential of BLR-200 for the treatment of systemic sclerosis (scleroderma). The company also presented data on its research on CCN proteins as ...

Dravet syndrome is a rare, severe, lifelong developmental and epileptic encephalopathy that begins in infancy and is marked by prolonged, often fever-triggered seizures that are difficult to control.

UCB SA agreed to pay $2 billion up front to acquire bispecific T-cell engager (TCE)-maker Candid Therapeutics Inc. and lead BCMA/CD3 TCE asset cizutamig (CND-106), continuing big pharma’s spree for ...

Antibody-drug conjugates (ADCs) comprising an antibody targeting folate receptor α (FOLR1; FR-α) covalently linked to a cytotoxic drug have been described in a Shanghai Pharmaceuticals Holding Co. Ltd ...